KN026
KN026 is a pharmaceutical drug with 9 clinical trials. Currently 3 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
5
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
1 of 1 finished
0.0%
0 ended early
3
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer
JSKN003 Combined Treatment of HER2-positive Gastric Cancer
A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer
Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
Clinical Trials (9)
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer
JSKN003 Combined Treatment of HER2-positive Gastric Cancer
A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer
Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer
KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma
Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer
All 9 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 9